Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real Study

NCT04951856 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04951856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04951856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 29, 2021
Completion date
May 22, 2028
Enrollment
2,166 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nstemi - non-st segment elevation mi, stemi - st elevation myocardial infarction